Interleukin-6 as a therapy target in oral squamous carcinoma

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 1, 2013, Pages 53-59

  Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiogenesis; Interleukin 6; Interleukin 6 receptor antibodies; Oral squamous carcinoma; Proliferation

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; SILTUXIMAB; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TOCILIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; CANCER EPIDEMIOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LYMPHANGIOGENESIS; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HUMANS; INTERLEUKIN-6; JANUS KINASES; MOUTH NEOPLASMS; RECEPTORS, INTERLEUKIN-6; STAT TRANSCRIPTION FACTORS;

EID: 84871212439     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.733368     Document Type: Review

References (39)

1. Van der Fits L, Out-Luiting JJ, van Leeuwen MA, et al. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome. J Invest Dermatol 2012;132:440-7
2. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 2011;71:5020-9
3. Adachi M, Cui C, Dodge CT, Bhayani MK. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol 2012; In press
4. Sen M, Joyce S, Panahandeh M, et al. Targeting STAT3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012; In press
5. Gioeli D, Mandell JW, Petroni GR, et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84 (Pubitemid 29048852)
6. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6 (Pubitemid 39006542)
7. Weber A, Hengge UR, Bardenheuer W, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 2005;24:6699-708 (Pubitemid 41486800)
8. Hoefer J, Schafer G, Klocker H, et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol 2012;180:2097-107
9. Lambert R, Sauvaget C, de Camargo Caneda M, Sankaranarayanan R. Epidemiology of cancer from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol 2011;23:633-41
10. Maybury C, Horowitz AM, Yan AF, et al. Maryland dentistś knowledge of oral cancer prevention and early detection. J Calif Dent Assoc 2012;40:341-50
11. Bhide SA, Ahmed M, Newbold K, et al. The role of intensity modulated radiotherapy in advanced oral cavity carcinoma. J Cancer Res Ther 2012;8(S1):S67-71
12. He G, Karin M. NF-kappa B and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21:159-68
13. Van Tubergen E, Vander Broek R, Lee J, et al. Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 2011;117:2677-89
14. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008;113:750-7
15. Rhodus NL, Ho V, Miller CS, et al. NF-kappa B dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42-5 (Pubitemid 40283497)
16. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1beta. IL-6, TNF-alpha, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res 1997;3:126-9
17. Nakano Y, Kobayashi W, Sugai S, et al. Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma. Jpn J Cancer Res 1999;90:858-66 (Pubitemid 29431365)
18. Woods KV, Adler-Stortzh K, Clayman GL, et al. Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7. Cancer Res 1998;58:3142-9 (Pubitemid 28335098)
19. Wang YF, Chang SY, Tai SK, et al. Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head Neck 2002;24:850-8
20. Chang MC, Wu HL, Lee JJ, et al. The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. J Biol Chem 2004;279:50676-83
21. Kayamori K, Sakamoto K, Nakashima T, et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol 2010;176:968-80
22. Tang CH, Chuang JY, Fong YC, et al. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappa B pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 2008;29:1483-92
23. Thomas GR, Chen Z, Leukinova E, et al. Cytokines IL-1 alpha, IL-6 and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol Immunother 2004;53:33-40 (Pubitemid 38161179)
24. Yadav A, Kumar B, Datta J, et al. IL-6 promotes head and neck tumor metastasis by inducing epithelialmesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011;9:1658-67
25. Sullivan NJ, Sasser AK, axel AE, et al. Interleukin-6 induces an epithelialmesenchymal transition phenotype in human breast cancer cells. Oncogene 2009;28:2940-7
26. Gasche JA, Hoffmann J, Boland CR, Goel A. Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer 2011;129:1053-63
27. Squarize CH, Castilho RM, Sriuranpong V, et al. Molecular cross-talk between the NFkappa B and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006;8:733-46 (Pubitemid 44465525)
28. Siavash H, Nikitakis NG, Sauk JJ. Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ (2) in oral squamous carcinoma cells. Br J Cancer 2004;91:1074-80 (Pubitemid 39336245)
29. Shinriki S, Jono H, Ueda M, et al. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol 2011;225:142-50
30. Bellezza I, Neuwirt H, Nemes C, et al. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 2006;169:2199-208 (Pubitemid 351181978)
31. Komyod W, Bohm M, Metze D, et al. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 2007;5:271-81 (Pubitemid 46569778)
32. Lee TL, Yeh J, van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006;5:8-19
33. GrossM, Liu B, Tan J, et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001;20:3880-7 (Pubitemid 32646198)
34. Demartis A, Bernassola F, Savino R, et al. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996;56:4213-18 (Pubitemid 26305018)
35. Trikha M, Corringham R, Klein B, Rossi J-F. Targeted anti-inerleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2013;9:4653-65
36. Yamamoto T, Kimura T, Ueta E, et al. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns. Oncology 2003;64:407-15 (Pubitemid 36682955)
37. Shinriki S, Jono H, Ota K, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009;15:5426-34
38. Van Zaanen HC, Lokhorst HM, Aarden LA, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. Br J Haematol 1998;102:783-90 (Pubitemid 28387063)
39. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma by curcumin (diferuloylmethane). Int J Cancer 2006;119:1268-75 (Pubitemid 44258799)